ACM 010
Alternative Names: ACM-010Latest Information Update: 04 Nov 2024
Price :
$50 *
At a glance
- Originator ACM Biolabs
- Class Anti-infectives
- Mechanism of Action Toll-like receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pneumonia
Most Recent Events
- 26 Sep 2024 ACM Biolabs plans a clinical trial for Pneumonia (ACM Biolabs pipeline, September 2024)
- 25 Sep 2024 Preclinical trials in Pneumonia in Singapore (unspecified route) prior to September 2024 (ACM Biolabs pipeline, September 2024)
- 25 Sep 2024 ACM Biolabs plans to file an IND application with the regulatory body for Pneumonia in Q4 2024 (ACM Biolabs pipeline, September 2024)